# Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

> **NCT01130272** · PHASE2 · COMPLETED · sponsor: **Furiex Pharmaceuticals, Inc** · enrollment: 807 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Eluxadoline
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01130272
- **Lead sponsor:** Furiex Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-28
- **Primary completion:** 2011-07-14
- **Final completion:** 2011-07-14
- **Target enrollment:** 807 (ACTUAL)
- **Last updated:** 2019-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130272, "Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01130272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*